How does AbbVie (ABBV) make money?

AbbVie (ABBV) generates revenue primarily from SKYRIZI, which accounted for 31.2% of total revenue in TTM through Q1 2026. The company reported $62.82B in revenue and converted 5.8% of it into net profit, equivalent to roughly $3.64B in net income — what's left after the cost of revenue, operating expenses, interest, and income taxes.

What is the gross profit margin of AbbVie (ABBV)?

AbbVie (ABBV) reported a gross profit margin of 70.7% in TTM through Q1 2026, equivalent to $44.40B in gross profit on $62.82B in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of AbbVie (ABBV)?

AbbVie (ABBV) reported an operating profit margin of 27.6% in TTM through Q1 2026, equivalent to $17.34B in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of AbbVie (ABBV)?

AbbVie (ABBV) reported a net profit margin of 5.8% in TTM through Q1 2026, equivalent to $3.64B in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is AbbVie (ABBV) profitable?

Yes. AbbVie (ABBV) reported $3.64B in net income for TTM through Q1 2026, with a net profit margin of 5.8%. The company earned more from its operations than it paid out in costs, interest, and income taxes, leaving positive earnings on the bottom line.

How much does AbbVie (ABBV) invest in research and development?

AbbVie (ABBV) invested $9.50B in research and development during TTM through Q1 2026, roughly 15.1% of total revenue. R&D spending funds the company's future product pipeline and is expensed in full on the income statement rather than capitalised, which makes the operating margin sensitive to how aggressively management chooses to reinvest in innovation.

How much does AbbVie (ABBV) spend on capital expenditures?

AbbVie (ABBV) spent $359.00M on capital expenditures (CapEx) during TTM through Q1 2026, roughly 0.6% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does AbbVie (ABBV) generate?

AbbVie (ABBV) generated $20.86B in free cash flow during TTM through Q1 2026, a free-cash-flow margin of 33.2%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

What is the effective tax rate of AbbVie (ABBV)?

AbbVie (ABBV) had an effective tax rate of 39.1% in TTM through Q1 2026. The effective rate is the actual share of pre-tax income paid as income taxes and can differ materially from the statutory rate due to foreign earnings mix, tax credits (such as R&D), share-based compensation deductions, and one-off discrete items.

What are the main business segments of AbbVie (ABBV)?

AbbVie (ABBV) reports revenue across 21 reportable product segments, led by SKYRIZI at 31.2% of total revenue in TTM through Q1 2026. See the revenue-by-segment table on this page for the full breakdown and how each segment feeds into the income-statement waterfall above.

Where does AbbVie (ABBV) generate most of its revenue?

UNITED STATES is the largest geographic market for AbbVie (ABBV), accounting for 96.1% of revenue in the most recent annual filing. The complete regional split — including international markets and any Rest-of-World rollup — is shown in the revenue-by-geography table on this page.

How AbbVie Makes Money: 2026 Visual Revenue Map

AbbVie (ABBV) Income Statement Flow — TTM through Q1 2026

Calculated from the four most recent reported quarters, ending March 31, 2026 (reported May 8, 2026).

AbbVie (ABBV) Revenue by Product Segment — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported segments changed mid-year.

Revenue contribution by product segment for AbbVie (ABBV) in TTM through Q1 2026.
Segment	Revenue (USD)	% of total
SKYRIZI	$19.62B	31.2%
RINVOQ	$9.17B	14.6%
HUMIRA	$4.33B	6.9%
Botox Therapeutic	$4.12B	6.6%
Vraylar	$3.96B	6.3%
Other Products	$3.06B	4.9%
VENCLEXTA	$3.05B	4.9%
Botox Cosmetic	$2.86B	4.6%
Other segments	$12.64B	20.1%
Total	$62.82B	100%

SKYRIZI$19.62B
RINVOQ$9.17B
HUMIRA$4.33B
Botox Therapeutic$4.12B
Vraylar$3.96B
Other Products$3.06B
VENCLEXTA$3.05B
Botox Cosmetic$2.86B
Other segments$12.64B
Total$62.82B

AbbVie (ABBV) Revenue by Geography — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported regions changed mid-year.

Revenue contribution by geographic region for AbbVie (ABBV), TTM through Q1 2026
Region	Revenue (USD)	% of total
UNITED STATES	$47.01B	96.1%
Non-US	$1.92B	3.9%
Total	$48.93B	100%

UNITED STATES
Non-US
Total

Revenue Breakdown — TTM through Q1 2026

In TTM through Q1 2026, AbbVie (ABBV) reports revenue across 21 operating segments; the largest segment was SKYRIZI at 31.2%, followed by RINVOQ (14.6%) and HUMIRA (6.9%). Separately, by end-market geography, UNITED STATES accounted for 96.1% of revenue, followed by Non-US (3.9%).

Frequently asked questions

Data & methodology

AbbVie (ABBV) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview

ABBV Overview

Counters

Income Statement

Cash Flow

Capital Return

Forecast & Valuation